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Abstract: Autologous stem cell transplantation is the preferred treatment option for younger 
patients with symptomatic plasma cell myeloma. Most patients with newly diagnosed plasma 
cell myeloma receive 3–4 cycles of induction chemotherapy to achieve a level of disease control 
before proceeding to stem cell transplant. The ideal induction regimen for transplant-eligible 
patients shall allow more patients to proceed with transplant, rapidly and effectively control the 
disease, reverse disease-related complications, avoid early death, and is associated with minimal 
acute and long-term toxicities. Because of the concerns of potential damages to hematopoietic 
stem cells, alkylating agent regimens, specifically melphalan, are usually avoided for induction 
in transplant-eligible patients. Before the advance of immunomodulatory agents (IMiD) and 
proteasome inhibitors, the combination of vincristine, adriamycin, and dexamethasone (VAD) 
and variants were the most commonly used induction regimens. Recent reports as discussed in 
this review suggests that VAD is no longer the induction chemotherapy of choice for transplant 
eligible patients. Newer regimens incorporating IMiD and/or proteasome inhibitor into the induc-
tion regimen improve response rates and progression-free survival before and after the transplant 
and are evolving as the treatment of choice. Here, we review the available data on these newer 
induction regimens and to evaluate the potential impacts on the patient outcomes.
Keywords:  plasma cell myeloma, induction chemotherapy, autologous stem cell 
transplantation
Introduction
Based on the results of two landmark studies published in the New England Journal 
of Medicine in 1996 and 2003, by the Intergroupe Francophone de Myeloma (IFM), 
France,1 and Medical Research Council (MRC), United Kingdom,2 respectively, upfront 
autologous stem cell transplant (ASCT) is considered the preferred treatment option 
for younger patients with newly diagnosed plasma cell myeloma. Practice guidelines 
from both sides of the Atlantic endorse this treatment approach,3,4 although the defi-
nition of “young,” and hence transplant eligibility, differs. In Europe patients aged 
60–65 years are usually considered to be eligible for transplant, but there is no upper 
age limit in the US. Although it is not the purpose of this review to address transplant 
eligibility, in our opinion, age alone should not be an exclusion criterion for ASCT. 
It is the responsibility of the treating physician to help patients establish their treat-
ment goals and to discuss the risks and benefits of all treatment options available to 
them. It is also important for physicians and patients to be aware of the impact that 
certain induction regimens may have on potential stem cell harvest, which may affect 
eligibility for a future transplant.Clinical Pharmacology: Advances and Applications 2010:2 72
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Most patients with newly diagnosed plasma cell myeloma 
are treated with 3–4 cycles of induction chemotherapy in an 
attempt to achieve a level of disease control before proceeding 
to stem cell transplant. Induction chemotherapy is also intended 
to relieve symptoms, correct hypercalcemia, improve renal 
function, and improve performance status in preparation for 
a transplant. Before the introduction of novel agents, such 
as immunomodulatory agents and proteasome inhibitors, 
induction chemotherapy has not been shown to improve 
outcomes in patients undergoing ASCT. In fact, for patients 
with primary progressive plasma cell myeloma, multiple 
induction attempts are discouraged, since favorable outcomes 
with autologous stem cell transplant have been demonstrated 
in this setting.5 In the era before novel therapies, complete 
responses were uncommon, thereby making induction regimens 
less important and less relevant. The ideal induction regimen for 
a transplant-eligible patient should allow more patients to pro-
ceed with transplant. It should rapidly and effectively control 
disease, reverse disease-related complications, decrease the risk 
of early death, be easily tolerated with minimal/manageable 
acute and long term toxicities, and not interfere with the ability 
to harvest and collect stem cells for future stem cell transplanta-
tion. Furthermore, the regimen should improve response rates 
before and after ASCT and ultimately improve the progression-
free survival (PFS) and overall survival (OS).
Melphalan–prednisone  
and vincristine–adriamycin–
dexamethasone
The combination of melphalan–prednisone (MP) had been 
the standard induction regimen for many decades until the 
advent of ASCT.6 However, the regimen has fallen out of 
favor because of the concern that exposure to alkylating 
agents can adversely affect stem cell harvest. Although a few 
cycles of MP probably will not preclude a successful harvest, 
newer induction regimens which appear to have faster and 
higher response rates when compared with MP should be 
considered (see below) in transplant-eligible patients.
Before the advances in novel agents such as immu-
nomodulating drugs (IMiDs) and proteasome inhibitors 
(bortezomib), vincristine–doxorubicin–dexamethasone 
(VAD) was the most commonly used induction regimen for 
transplant-eligible patients.7 In VAD, the chemotherapeutic 
agents are given as a continuous intravenous infusion which, 
in addition to being inconvenient, also exposes patients to 
catheter-related complications. Rifkin et al substituted Doxil® 
for doxorubicin (DVD) and demonstrated a similar efficacy 
and toxicity profile to VAD.8 Since the activity of the VAD 
and DVD regimens is thought to be primarily because of the 
high-dose dexamethasone component, some hematologists 
and oncologists use dexamethasone alone as a “safer” and 
“better tolerated” alternative induction therapy for plasma cell 
myeloma.9 The typical high-dose dexamethasone using as a 
single agent (40 mg orally days 1–4, 9–12, 17–20) is associ-
ated with lower response rates (approximately 45%) when 
compared with VAD and DVD, without significant improve-
ment in toxicity profile. In a randomized study comparing 
dexamethasone with thalidomide-dexamethasone (TD), the 
authors reported an early mortality of 10% which underscores 
the true toxicity of high-dose dexamethasone.10 The investi-
gators from the European Cooperative Group for Bone and 
Marrow Transplantation (ECOG) reported similar results in 
another Phase III study comparing high-dose dexamethasone 
with lenalidomide/low-dose dexamethasone.11
Thalidomide-dexamethasone
In the early 2000s, a novel oral regimen using the combination 
of thalidomide–dexamethasone was introduced. The initial 
Phase II studies demonstrated response rates of 64%–76% 
which compared favorably with VAD.12 Because the com-
bination yielded improved response rates and offered the 
advantage of an oral regimen, TD soon emerged as the pre-
ferred induction regimen for transplant-eligible patients. In a 
subsequent Phase III randomized study conducted by ECOG 
comparing T with TD;10 the best response rate with four cycles 
of therapy was 63% versus 41%, respectively (P = 0.0017). 
In another confirmatory study that included 470 patients with 
newly diagnosed myeloma, TD was compared with placebo-
dexamethazone (PD).13 According to the European Bone and 
Marrow Transplant (EBMT) response criteria, 63% of patients 
randomized to the TD arm achieved a complete response 
(CR) + a partial response (PR) compared with 46% in the 
PD arm (P  0.001). Based on the International Myeloma 
Working Group criteria, 43% achieved CR/very good partial 
response (VGPR) in the TD arm compared with 15.8% in the 
PD arm (P  0.001) with the median time to best response 
of 8.3 weeks versus 20.1 weeks, respectively. Notably, TD 
had no significant effect on stem cell yield. These two ran-
domized studies further supported the practice of using tha-
lidomide–dexamethasone as the induction regimen of choice 
in transplant-eligible patients, although it is not a “benign” 
regimen. In the ECOG study, 17% patients in the TD arm 
developed deep vein thrombosis, compared with 3% in the 
control arm. Furthermore, Grade 3 or higher nonhematologic 
toxicities were seen more commonly in the TD arm (67% 
vs 43%). The early mortality (first four months) was 7% in Clinical Pharmacology: Advances and Applications 2010:2 73
induction chemotherapy before ASCT in plasma cell myeloma Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
the TD arm compared with 11% in the dexamethasone arm; 
although the TD arm was comparable with the dexamethasone 
arm, an early death rate of 7% was still unacceptably high. 
Both studies, however, failed to demonstrate any improve-
ment in time to progression, PFS, and OS after autologous 
stem cell transplantation, although these were not the primary 
endpoints. Macro et al reported a prospective study (albeit 
in abstract form), comparing TD with VAD, where 44% of 
patients in the TD arm achieved at least VGPR after ASCT, 
compared with 42% in the VAD arm.14 Of note, the use of TD 
was once again associated with a higher incidence of venous 
thromboembolism (VTE). Thus, taking into consideration 
the above data, we note that the improved response rates 
obtained with TD in comparison with VAD did not translate 
into improved outcomes after ASCT. Rather, the combination 
was associated with increased toxicities, thereby speaking 
against the routine use of thalidomide-dexamethasone as 
induction therapy prior to ASCT, given that the benefits when 
compared with VAD/DVD are, at best, marginal.
Lenalidomide–dexamethasone
Based on the assumption that lenalidomide is more potent 
and less toxic than thalidomide, investigators from the Mayo 
Clinic tested lenalidomide–dexamethasone in the upfront set-
ting with 67% of patients achieving VGPR or better in a pilot 
study.15 Approximately, 50% of patients experienced Grade 3 
or higher non-hematologic toxicity, similar to rates seen with 
dexamethasone alone. Clearly, this regimen needed improve-
ment. In an attempt to reduce the toxicity of lenalidomide/
standard-dose dexamethasone, ECOG conducted a Phase III 
prospective study comparing lenalidomide/standard-dose 
dexamethasone with lenalidomide/low-dose dexametha-
sone (40 mg dexamethasone weekly). The toxicity rates 
were significantly higher with lenalidomide/standard-dose 
dexamethasone compared with lenalidomide/low-dose dexa-
methasone.11 Early mortality rates (first four months) were 
5% versus 0.5%, favoring the lenalidomidelow-dose dexa-
methasone arm. As with thalidomide, thromboprophylaxis is 
required for patients who received lenalidomide-containing 
regimens. Four hundred and forty-five patients were included 
in the study; 223 randomized to lenalidomide/standard-
dose dexamethasone and 222 to lenalidomide/low-dose 
dexamethasone. With a median followup of 17 months, 
OS was significantly superior with lenalidomide/low-dose 
dexamethasone (P  0.001); one-year survival was 96% 
versus 87%, respectively, and 18-month survival 91% versus 
80%. OS differences in favor of the low-dose dexamethasone 
arm were seen in patients younger than 65 years (P = 0.022; 
one-year survival rate 97% versus 92%) as well as patients 
65 years and older (P = 0.002; one-year survival rate 94% 
versus 83%), respectively.
Of some concern, recent reports suggest that prior expo-
sure to lenalidomide may adversely affect stem cell mobiliza-
tion kinetics.16 Thus, lenalidomide should be used cautiously 
in transplant-eligible patients, and stem cell harvest should 
be considered before the patients receive multiple cycles 
of lenalidomide. In a retrospective study of 472 patients, 
investigators from the Mayo Clinic did not find any dif-
ferences in post-transplant outcomes in patients receiving 
VAD, dexamethasone alone, thalidomide–dexamethasone 
or lenalidomide–dexamethasone.17
In summary, the combination of lenalidomide and low-
dose dexamethasone is an effective induction regimen which 
is well tolerated and associated with low early mortality. It 
should be considered as one of the options for transplant-
eligible patients with newly diagnosed symptomatic plasma 
cell myeloma. However, lenalidomide–dexamethasone has 
not been compared directly with VAD or a bortezomib-based 
induction regimen before ASCT. A Phase III prospective 
study will be required to define better the role of lenalido-
mide/low-dose dexamethasone as induction for transplant-
eligible patients.
Thalidomide–doxorubicin–
dexamethasone
It is somewhat unfair to compare a two-drug regimen that 
contains thalidomide and dexamethasone with a three-drug 
regimen such as VAD, because doxorubicin is known to be an 
effective agent in the treatment of plasma cell myeloma. In a 
Phase III prospective study conducted by the Dutch Group 
(HOVON 50), thalidomide–doxorubicin–dexamethasone 
(TAD) was compared with VAD as induction therapy for 
transplant-eligible patients.18,19 Between November 2001 
and May 2005, 556 patients were enrolled in the study. 
The primary endpoint was event-free survival (EFS). TAD 
yielded improved response rates when compared with VAD 
after ASCT (PR: 87% versus 79%, P  0.01; VGPR: 65% 
versus 54%, P  0.01; CR: 30% versus 21%, P = 0.03). TAD 
also showed improved EFS (33 months versus 22 months; 
P  0.001) and PFS (33 months versus 25 months; P  0.001) 
when compared with VAD after ASCT. Because of a relatively 
short followup, OS benefit has not been demonstrated. In 
addition, with the availability of novel agents for salvage at 
the time of disease progression, it will be increasing difficult 
to show a survival benefit. Although the new combination 
of TAD compared favorably with VAD, regimens containing Clinical Pharmacology: Advances and Applications 2010:2 74
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high-dose dexamethasone and/or thalidomide are associ-
ated with an increased risk of VTE, as well as the significant 
side effects from high-dose dexamethasone. One may argue 
that by using a lower dose of dexamethasone, similar to the 
ECOG study described earlier using lenalidomide/low-dose 
dexamethasone,11 the toxicity profile may improve. However, 
there are no good data to support this approach.
Bortezomib-containing regimens
In a Phase III randomized four-arm study (IFM 2005-01), 
Harousseau et al compared bortezomib–dexamethasone   
(±dexamethasone–cyclophosphamide–etoposide–cisplatin 
[DCEP] consolidation) with VAD (± DCEP consolidation).20 
Patients received four cycles of VAD or bortezomib–
  dexamethasone ± two cycles of DCEP followed by a single 
cycle of high-dose melphalan (200 mg/m2) with autologous 
stem cell rescue. For patients who failed to achieve VGPR 
after the first transplant, a second autologous stem cell 
  transplant, or reduced intensity allogeneic stem cell transplant, 
was considered. The response rates (CR + near CR,  VGPR 
and PR) before and after ASCT all favored the bortezomib–
dexamethasone arm. The best responses after second 
autologous stem cell transplant were CR/near CR in 32% 
and 39% (P  0.001), VGPR in 47% and 68% (P  0.001) 
for the VAD arm versus the bortezomib–dexamethasone 
arm, respectively. The estimated two-year PFS was 60% in 
the VAD arm versus 69% in the bortezomib–dexamethasone 
arm (P = 0.0115). Sonneveld et al compared three cycles of   
VAD with three cycles of bortezomib–adriamycin–
  dexamethasone (PAD) followed by ASCT.21 PAD delivered 
improved response rates compared with VAD. After the 
transplant, while 80% of patients who received PAD achieved 
VGPR; only 50% of patients who received VAD (P = 0.019) 
achieved a VGPR. Sixteen percent of patients developed 
Grade 3–4 neuropathy in the PAD arm versus 6% in VAD 
arm. In a Phase III prospective, randomized study conducted 
by the Italian Multiple Myeloma Network ( GIMEMA), Cavo 
et al compared TD-ASCT with VTD-ASCT, which showed 
that response rates and PFS were superior in the VTD arm.22 
On an intent-to-treat analysis, post-transplant CR rates were 
41% in the VTD arm versus 20% in the TD arm (P  0.001). 
Two-year PFS was significantly superior with VTD com-
pared with thalidomide–dexamethasone (90% versus 80%, 
P = 0.009) but there was no difference in OS.
The above-mentioned studies, although reported in 
abstract form, suggest that bortezomib-based regimens com-
pare favorably with VAD and TD. These novel regimens not 
only improve response rates before and after transplant, but 
have also demonstrated improvement in PFS, which is a strong 
surrogate marker for OS. In addition, multiple studies23–25 also 
suggest that bortezomib may be able to overcome the adverse 
prognostic effect of unfavorable cytogenetics. Furthermore, 
no dose adjustments are required for patients with renal 
insufficiency, even when they are receiving hemodialysis. 
In contrast, dose adjustment for lenalidomide is required for 
patient with renal insufficiency. It is also important to note 
that bortezomib-based regimens do not affect stem cell yields 
and thromboprophylaxis is not necessary. On the other hand, 
10%–20% of patients treated with bortezomib will develop 
significant peripheral neuropathy. Nonetheless, data from 
large, well-controlled studies suggested that most patients 
with bortezomib-induced peripheral neuropathy improve or 
completely resolve at a median interval of three months.
Future directions
Recent reported Phase II studies that include both lenalido-
mide and bortezomib in multiagent regimens or sequential 
regimens have demonstrated 90%–100%  PR, 60%–71%   
VGPR and 32%–36% CR/nCR.26–28 In general, three or four 
cycles of induction chemotherapy are given before stem cell 
transplant. It is unclear whether a higher quality of response 
before stem cell transplant may be beneficial or may lead to 
increased transplant-related toxicity. In patients with acute leuke-
mia, stem cell transplant is usually performed after achievement 
of remission, in whom the outcomes are more favorable than 
in patients who are transplanted with active disease. Although 
utilizing stem cell transplant as consolidation, similar to that 
employed in patients with acute leukemia and lymphoma, makes 
absolute sense, the role of stem cell transplant in patients with 
plasma cell myeloma who have achieved a complete remission 
is currently unknown. These important questions can only be 
answered in the context of a Phase III randomized trial.
Conclusion
In summary, outside of the setting of a clinical trial, 
  transplant-eligible patients should be treated with 3–4 cycles 
of an induction regimen containing a novel agent before stem 
cell transplant. Examples include lenalidomide/low-dose 
dexamethasone, bortezomib–dexamethasone, PAD or VTD. 
For patients with high risk disease, particularly associated 
with unfavorable cytogenetics, the current literature favors 
the use of a bortezomib-based regimen, with or without an 
IMiD. For patients with pre-existing neuropathy, bortezomib 
should be used with caution. For patients with a previous 
history of thrombosis, or those at high risk of developing 
VTE, IMiD-containing regimens, although not absolutely Clinical Pharmacology: Advances and Applications 2010:2
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contraindicated, should be avoided, especially given that 
other effective options are available.
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